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Aim: To evaluate the association between lower urinary tract symptoms (LUTS) and metabolic syndrome (MS) in women.
Materials and methods: A total of 155 women with LUTS were included in the study. LUTS were evaluated using the International
Prostate Symptom Score (IPSS) and the Bristol Female Lower Urinary Tract Symptoms (BFLUTS) questionnaire. Besides total IPSS,
voiding and storage IPSS were calculated separately. Diagnosis of MS was made according to the consensus report of the International
Diabetes Foundation. The patients were classified into 3 groups: those without MS (group 1), those with 3 risk factors of MS (group 2),
and those with more than 3 risk factors of MS (group 3). The groups were compared regarding IPSS and BFLUTS data.
Results: Of the patients, 37.4% (n = 58) had MS, while 62.6% (n = 97) did not. There were significant differences between group 1 and
group 3 regarding BFLUTS-FS (filling symptoms), BFLUTS-QoL (quality of life), storage IPSS, and total IPSS. However, concerning
BFLUTS-VS (voiding symptoms), BFLUTS-sex, and voiding IPSS, there was not any difference among the 3 groups.
Conclusion: The results of our study have shown that women with more than 3 MS components might have more storage symptoms
than women without MS.
Key words: Female, lower urinary tract symptoms, metabolic syndrome

1. Introduction
Metabolic syndrome (MS) has a combination of risk factors
that increase the risk of developing cardiovascular disease
and type 2 diabetes (1–4). Those risk factors are glucose
intolerance, atherogenic lipid profile, hypertension,
and abdominal obesity (5–8). The prevalence of MS is
increasing worldwide. MS is seen in 10% of persons with
normal glucose tolerance, in 50% of those with abnormal
glucose tolerance, and in 80% of type 2 diabetics (9). For
people over age 30, the prevalence of MS in Turkey is 27%
for men and 38.6% for women (10).
Lower urinary tract symptoms (LUTS) represent a
collection of symptoms associated with bladder filling
(storage) and voiding. Storage symptoms include urgency,
nocturia, and frequency; voiding symptoms consist of
poor stream, hesitancy, terminal dribbling, and incomplete
voiding (11). Age-related structural and functional changes
in the lower urinary tract can cause LUTS in aging women
(12). Nowadays, MS and its components are accepted as
a major health problem, especially in modern societies
* Correspondence: kaanaktas73@hotmail.com
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(13). The syndrome has effects on all systems just as in
the urinary tract (14). The increase observed in frequency
and severity of the patients’ LUTS is thought to be related
to MS components. Multiple studies demonstrated a
strong independent association between LUTS and MS
components in men (15,16). However, not as many
studies investigated the same topic in women (17,18). In
the present study, we aimed to evaluate the association
between LUTS and MS in our female patients.
2. Materials and methods
Between January and July 2011, 155 women who applied
to our outpatient urology clinic with LUTS were included
in this study. Our urology clinic is a tertiary referral center
located in the capital city of Turkey, Ankara. Patients
with neurological disease, pelvic organ prolapse, previous
pelvic surgery, and urinary tract infection were excluded
from the study. Informed consent was obtained from each
patient.
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A detailed medical history was obtained initially and
systemic diseases such as diabetes mellitus and hypertension
were asked about in particular. LUTS were evaluated using
Turkish validated versions of the International Prostate
Symptom Score (IPSS) and the Bristol Female Lower
Urinary Tract Symptoms Index Scored Form (BFLUTSSF). For the IPSS, each symptom was graded from 0
(not at all) to 5 (always) by symptom frequency. Scores
of these individual symptoms are aggregated to form
a total symptom score range of 0 to 35. To discriminate
between voiding and storage symptoms, the voiding IPSS
(incomplete emptying, intermittency, weak stream, and
straining) and the storage IPSS (frequency, urgency, and
nocturia) were calculated separately besides the total
IPSS. Nocturia was assessed as the number of times the
patient arose at night to urinate after falling asleep. The
BFLUTS-SF questionnaire comprises 3 subscales: filling
symptoms (BFLUTS-FS), voiding symptoms (BFLUTSVS), and incontinence symptoms (BFLUTS-IS), with the
addition of single subscales for sexual function (BFLUTSsex) and quality of life (BFLUTS-QoL). Blood pressures,
body weights, body heights, and waist circumferences of
all patients were measured. Body mass index (BMI) was
calculated as body weight divided by the square of body
height. Blood tests including serum glucose, triglyceride,
high-density lipoprotein cholesterol (HDL-C), and insulin
were performed. Blood samples were collected from the
patients after one night of fasting. Fasting serum insulin
levels were measured using the radioimmunoassay method

(MP Biomedical and Diagnostics, San Diego, CA, USA).
Metabolic syndrome diagnosis was made according to the
consensus report of the International Diabetes Foundation
(IDF) (19). According to IDF 2005 criteria of MS, central
obesity was defined by waist circumference of women of
>80 cm and 2 of the 4 factors mentioned in the IDF 2005
criteria (triglyceride > 150 mg/dL, HDL-C < 50 mg/dL,
blood pressure > 130/80 mmHg, and fasting blood sugar
> 100 mg/dL).
The results were given as means ± standard deviations.
Two groups were compared using Student’s t-test. Multiple
comparisons were performed by one-way ANOVA and
Tukey tests. P-values lower than 0.05 were considered
significant.
3. Results
Of the 155 patients, 24.2% (n = 58) had MS, while 75.8% (n
= 97) did not. Furthermore, 55% of patients with MS had
3 components and 45% had more than 3. Mean age, waist
circumference, BMI, fasting blood glucose, triglyceride,
filling IPSS, and 3 subscales of BFLUTS (FS, IS, QoL) of
patients with MS were significantly higher than those of
patients without MS. However, mean serum HDL-C level
of patients with metabolic syndrome was significantly
lower than in patients without MS. Mean serum insulin
level, voiding IPSS, and the other subscales of BFLUTS
(VS, sex) were not significantly different between the
patients with and without MS (Table 1).

Table 1. The clinical and laboratory data of women in 2 groups.
Non-MS group (n = 97)

MS group (n = 58)

P*

Age (years)

42.01 ± 12.1

50.6 ± 11.5

0.0001

BFLUTS-FS

6.72 ± 3.8

8.4 ± 3.6

0.006

BFLUTS VS

2.71 ± 2.5

2.8 ± 2.9

0.86

BFLUTS-IS

3.9 ± 3.7

6.5 ± 5.8

0.0001

BFLUTS-sex

0.6 ± 1.04

0.8 ± 1.3

0.23

BFLUTS-QoL

4.8 ± 4.3

6.8 ± 5.3

0.01

Voiding IPSS

3.8 ± 4.6

4.8 ± 5.6

0.25

Storage IPSS

5.1 ± 3.8

6.9 ± 4.7

0.01

Total IPSS

8.9 ± 7.3

11.7 ± 9.1

0.03

BMI (kg/m2)

25.8 ± 4.1

30.5 ± 4.6

0.0001

Waist circumference (cm)

91.9 ± 19.9

110.0 ± 16.9

0.0001

Glucose (mg/dL)

85.2 ± 16.6

117.5 ± 44.6

0.0001

HDL-C (mg/dL)

48.1 ± 10.8

39.9 ± 8.6

0.0001

Triglyceride (mg/dL)

102.6 ± 54.0

167.9 ± 88.4

0.0001

9.6 ± 8.3

13.3 ± 13.0

0.053

Insulin (µIU/mL)
* Student’s t-test
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The patients were then classified into 3 groups: those
without MS (group 1), those with 3 risk factors of MS
(group 2), and those with more than 3 risk factors of MS
(group 3). The groups were compared regarding the 5
subscales of BFLUTS, voiding, filling, and total IPSS. There
was a significant difference between group 1 and group 3
in regard to BFLUTS-FS, BFLUTS-QoL, filling IPSS, and
total IPSS, while there was not between group 1 and group
2 or between group 2 and group 3. There were significant
differences between group 1 and group 2 and between
group 1 and group 3 in regard to BFLUTS-IS, while there
was not between group 2 and group 3. However, in regard
to BFLUTS-VS, BFLUTS-sex, and voiding IPSS, there was
not any difference among the 3 groups (Table 2).
4. Discussion
A growing number of recent studies have underscored the
association between LUTS and MS components in males
(15,16,20,21). In a study including 158 patients with LUTS
secondary to benign prostatic hyperplasia, Hammerstein
et al. found that patients with the components of MS
had bigger prostates than those without, and the annual
increase in prostate volumes was also higher. In addition,
annual prostatic volume increase was positively correlated
with obesity, fasting insulin levels, and systolic blood
pressure, and negatively correlated with HDL-C levels
(22). Kupelian et al. supported the presence of a link

between MS and LUTS. In the Boston Area Community
Health study, they reported that MS was associated with
symptoms of voiding rather than filling (23).
The prevalence of LUTS is getting higher in women.
In the longitudinal report of Wennberg et al., a marked
increase was observed in LUTS of women over a period of
16 years (24). Results of the EPIC study were parallel with
theirs and demonstrated that LUTS were prevalent in both
men and women, with storage LUTS being more prevalent
than voiding (25).
Tai et al. evaluated the effect of MS components on LUTS
in their study with 850 type 2 diabetic women (17). They
detected moderate to severe LUTS in 36.7% of patients and
the increase in both total and storage symptom scores was
greater than that of voiding in patients with MS compared
to those without. Finally they concluded that the increase
in symptom scores of patients with 4 or 5 components of
MS was significant. Similarly, in our study, storage IPSS
and BFLUTS-FS of patients with LUTS and more than 3
components of MS were significantly higher than in both
the patients with 3 or fewer MS components and those
without MS. In another recent study, MS correlated highly
with overactive bladder in female patients (26). In the study
of Hong et al., significant differences were observed in LUTS
depending on the presence or absence of MS in females, but
not in males. The authors underscored the sex differences in
the morbidity rate of MS and its effect on LUTS (27).

Table 2. BFLUTS and IPSS data of women in 3 groups.
Non-MS
(group 1)
(n = 97)

MS
3 risk factors
(group 2)
(n = 32)

MS
>3 risk factors
(group 3)
(n = 26)

P*

BFLUTS-FS1

6.72 ± 3.8

8.1 ± 3.5

8.8 ± 3.8

0.02

BFLUTS VS

2.71 ± 2.5

2.6 ± 3.0

3.0 ± 2.8

0.80

BFLUTS-IS2

3.9 ± 3.7

6.3 ± 5.6

6.7 ± 6.1

0.002

0.6 ± 1.04

0.7 ± 1.0

1.0 ± 1.5

0.26

4.8 ± 4.3

6.4 ± 5.1

7.3 ± 5.6

0.03

Voiding IPSS

3.8 ± 4.6

3.8 ± 5.4

6.1 ± 5.8

0.11

Storage IPSS4

5.1 ± 3.8

5.8 ± 4.1

8.2 ± 5.1

0.003

Total IPSS

8.9 ± 7.3

9.6 ± 8.3

14.3 ± 9.5

0.009

BFLUTS-sex
BFLUTS-QoL

5

3

* One-way ANOVA
1
Significant difference between groups 1 and 3 (P = 0.03, Tukey test).
2
Significant differences between groups 1 and 2 and between groups 1 and 3 (P = 0.024 and P = 0.012,
respectively, Tukey test).
3
Significant difference between groups 1 and 3 (P = 0.045, Tukey test).
4
Significant difference between groups 1 and 3 (P = 0.002, Tukey test).
5
Significant difference between groups 1 and 3 (P = 0.006, Tukey test).
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MS components have been thought to cause and
increase storage and voiding symptoms both in men and
women as a result of several pathophysiological pathways.
One of the possible pathophysiological pathways associated
with MS components is structural and functional
bladder disorder caused by chronic bladder ischemia
secondary to microvascular atherosclerosis (17,28).
Bladder overactivity, fibrosis, neuropathy, and decreased
bladder compliance as a result of arterial insufficiency
were shown in rabbit models (29). In addition, long-term
hyperglycemia-induced damage and viability reduction
in parasympathetic pelvic ganglion neurons are the other
possible mechanisms. Animal studies also supported

that hypothesis; elevated serum glucose levels increased
neuronal apoptosis in parasympathetic neurons more
than in sympathetic pairs (30,31). This unbalanced loss
in autonomic neurons leads to sympathetic overactivity,
and thus voiding symptoms secondary to bladder neck
obstruction and decreased bladder contractility might
develop. All these studies emphasize the association
between MS components and LUTS.
The results of our study have shown that women with
more than 3 MS components might have more storage
symptoms than women without MS. Our results and their
underlying mechanisms need to be supported by future
studies with larger patient population.
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